Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. - Test2 - elhamkhani - TriplyDB

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

http://www.wikidata.org/entity/Q34467145

about

Lipid-lowering efficacy of atorvastatin Lipid lowering efficacy of atorvastatin Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation Commentary on the clinical management of metabolic syndrome: why a healthy lifestyle is important.Do statins increase and Mediterranean diet decrease the risk of breast cancer?Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers Role of bile acid sequestrants in the treatment of type 2 diabetes Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.Dose-dependent effects of atorvastatin on myocardial infarction.Statins can delay insulin use and reduce diabetes-related diseases in Asian patients with type 2 diabetes Statin intake is associated with decreased insulin sensitivity during cardiac surgery.Different effects of statins on induction of diabetes mellitus: an experimental study.Differential metabolic actions of specific statins: clinical and therapeutic considerations Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival.Role of statins in coronary artery disease Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension Statin diabetogenicity: guidance for clinicians Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.Longitudinal associations between adiponectin and cardiac structure differ by hypertensive status: Coronary Artery Risk Development in Young Adults.Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease.Atorvastatin: safety and tolerability.Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?Do statins cause diabetes?Is statin-induced diabetes clinically relevant? A comprehensive review of the literature.Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.Statins, glycemia, and diabetes mellitus: another point of view.

P2860

Q24187301-1CE271B3-ACC3-4F74-8BCD-ADD5644C4BDD Q24202363-66B3717B-AB68-4C7F-AA27-4958A1778F4A Q24594814-1C145AE2-38C5-4EEF-8DD3-8AD114070EE2 Q28235346-AD86D1E7-A06D-44D8-A8CA-09DE37E175C9 Q34476797-7B8CC318-BB30-4B4D-A249-934796DBFF93 Q34500694-BE41F496-2DE7-467C-9315-A08230237BD1 Q34536800-5F6CA781-53C0-477E-AA73-FDEB30C04D33 Q34756897-1C677308-8B9C-4083-B514-96851B2B26B0 Q34877957-3B572FC2-0383-4436-BBFB-8E85E20B4722 Q35053761-2AF5773A-1C2D-472A-B50B-1C5E396E2E19 Q35065253-B46FBE05-CA2D-4D05-8815-A628AD178B35 Q35665099-A3B159A8-E833-4AEE-BFC7-C42845BD2A44 Q35669490-FD32E9A0-23EE-4584-94A5-A15DF8AB7A3C Q35821913-7FC03BF5-42A8-48A8-8D78-8C65D0A41A51 Q36153656-CA2720C0-0A7E-4896-AB0E-738DC9A18F69 Q36249616-A2FE21DB-BBEF-4AD7-B318-ABC479ABD9E4 Q36332395-FA7ABCD1-73D4-43A4-813E-52CA1E319B3C Q36406951-19320FA9-763F-412E-9C09-66A8753CFD97 Q36441669-B5B475E6-85EB-4A10-9B65-7FBE06C7847F Q36463044-A0438217-3156-4443-A0DE-68EE8CC67784 Q36470320-CA3E4C0D-2ED0-4754-B150-89557C1C640F Q36782651-E37DF2DA-2910-43B8-ADBD-87381AC1CD95 Q36837567-920E8165-4721-4016-B7CA-C68DC805A6B0 Q36837587-F3A86DEB-C110-4D02-84FE-EABBE81EEFA7 Q36888713-8256777F-4866-4396-9B77-766A5E243B54 Q37031309-5EAA4669-C7B7-4D32-9B79-F8DBD51DF8DB Q37166681-DD4A577C-AF98-4FE4-B89A-6EBA4A7B19D4 Q37193394-FB5A1123-4838-4F1E-ADF2-877AB3F0E21F Q37342403-0F408E59-BA95-4A22-8EE9-99A81CA45AA8 Q37367952-D15FACCF-7525-4A74-9FB4-86577A7B0EFC Q37653189-ED249CE4-CC86-4239-BADB-0DDE817EA7B2 Q37656313-3CB67291-FC2C-4A13-ADAB-37BD0017B930 Q37765562-7A630D8A-6C65-4CAF-9433-24B280C4ECA1 Q38010243-A35E3D23-9653-4003-BC0D-29E4EEFEFD85 Q38067263-E8A4C195-CD93-48D4-BA58-BA947815344E Q38086101-444252EF-94DC-4C51-8E40-19A3AABE8990 Q38174285-94F430DC-274A-4706-976C-3259DA1714ED Q38181977-9D7FE551-2412-4AA6-A875-3452B4274682 Q38222135-98434B75-CF10-4EE3-A3E7-E7219923E2A3 Q38257402-6C2FBA3F-7252-405A-9954-8E2E573E882E

P2860

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

http://www.wikidata.org/entity/Q34467145

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@ast

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@en

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@nl

type

label

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@ast

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@en

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@nl

prefLabel

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@ast

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@en

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@nl

P1433

Q34467145-59AE8FF0-9DBE-4563-88E6-5E646FFE3284

P1476

Q34467145-D5756E5E-3F7A-4C77-B642-93C089901636

P2093

Q34467145-173A9AC3-C2B7-40FB-AC32-D889522A19DB

Q34467145-1B263622-B64A-40A3-A10D-1163991376B0

Q34467145-487670C9-70B1-414A-8FE9-815365C30CEA

Q34467145-74A381BE-C2FF-4FE8-8D2B-3CE31E08D7A5

Q34467145-990B9DFD-EE6D-4E13-94F3-DE9E00FA3B99

Q34467145-A76D9AFE-0B18-4906-833A-874A64CF360F

Q34467145-A936118A-5275-4FF5-8881-F200EC921B3F

P2860

Q34467145-10C460BB-F604-4B96-A553-C9865F0D57A8

Q34467145-1B2683F5-9E3C-4CBF-92AB-B7902396DA91

Q34467145-1DE0CCB0-0AD3-4308-9B9C-A3B55B436D20

Q34467145-2EDDC375-C4EC-494E-A3D5-76B3C16E9F59

Q34467145-3A14A6A9-9DE9-44DA-850E-CBD152E8E1D6

Q34467145-3AF1A1A4-BC5C-4B65-AAB4-7F2257973162

Q34467145-5172CFEB-5B64-4CFA-A9EC-BDF81A99809D

Q34467145-5EC266BA-CFF2-4761-BE1D-A797F7B13DE8

Q34467145-702B9416-1ED4-4312-94AC-78086DC53E63

Q34467145-7CD80551-A6D6-4451-B84D-BA5E7FE2AB35

P304

Q34467145-5919D60E-DCA8-4293-9D06-0BF24CD233FE

P31

Q34467145-8908C80B-507B-4E4B-947A-8C4A14EA211E

P356

Q34467145-C738EBE9-6E63-4E6A-99C4-B08FC2F5190C

P407

Q34467145-C33F6CB0-5F1E-4419-82D4-3E69BA5BE0ED

P433

Q34467145-45DDE26A-1316-4C50-81C1-75247B6EA63B

P478

Q34467145-4D91B3E6-42CB-42F8-8184-49DB06B129A1

P577

Q34467145-DB02B432-B227-4FC5-B0CD-E840C184F8F7

P5875

Q34467145-8627945A-1DAF-4915-966E-980EF0A840E9

P698

Q34467145-779141C6-D05E-425D-9AAD-AE5792237FCA

P921

Q34467145-3EA26170-A6F1-48FB-A30A-AC93B8E70934

Q34467145-4B197A43-B456-4681-BF32-49FF99058D79

Q34467145-CF4DFD41-C98D-4FCE-9252-6E5574E8308D

P932

Q34467145-F26308A9-67AA-479A-B873-EEBD04E77407

P356

J.JACC.2009.10.053

P1433

Journal of the American College of Cardiology

P1476

Atorvastatin causes insulin re ...... hypercholesterolemic patients.

@en

P2093

Eak Kyun Shin

http://www.w3.org/2001/XMLSchema#string

Kwang Kon Koh

http://www.w3.org/2001/XMLSchema#string

Michael J Quon

http://www.w3.org/2001/XMLSchema#string

Seung Hwan Han

http://www.w3.org/2001/XMLSchema#string

Soo Jin Kim

http://www.w3.org/2001/XMLSchema#string

Yonghee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.

P304

1209-1216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2009.10.053

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42344513

http://www.w3.org/2001/XMLSchema#string

P698

20298928

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia

P932

3016087

http://www.w3.org/2001/XMLSchema#string